GHIAS BABAR (CFO & Head of Corp Development) received a stock award from BIOCRYST PHARMACEUTICALS INC
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 12/19/2025ACC: 0000882796-25-000038
Officer· CFO & Head of Corp Development
Since Jul 2025
+476.75K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
476.75K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+121.70K
Price / share
—
Trade value
—
% of position
82.8%
12/17/2025
147K→268.70K
Total
Net shares
+121.70K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/17/2025 | A · Award | +121.70K | — | — | 82.8% | 147K | 268.70K |
| Total | +121.70K | $0.00 | ||||||
Derivative Transactions1
Emp. Stock Option (Right to Buy)
Direct
Converts to
Common Stock
355.05K shares
Shares
+355.05K
Strike price
7.13
Held after
355.05K
Exercisable
—
12/17/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) Direct | Common Stock355.05K shares | 12/17/2025 | A · Award | +355.05K | 7.13 | — | 355.05K |